Mixed methods study of the potential therapeutic benefits from medical cannabis for patients in Florida

Luque, John S.; Okere, Arinze Nkemdirim; Reyes‐Ortiz, Carlos A.; Williams, Paula M.

doi:10.1016/j.ctim.2021.102669

Cited by 22 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include rigid guidelines for prescribing CBMPs, a paucity of empirical evidence on the effectiveness of CBMPs, lack of education on how to safely prescribe CBMPs, and associated stigma of cannabis use in the UK [ 2 , 3 , 4 ]. It is well documented that stigma can reduce utilisation of healthcare services and can negatively impact treatment [ 5 , 6 ]. It can also lead to chronic stress and anxiety, in addition to subsequent mental and physical problems that can cause individuals to feel isolated and withdrawn [ 5 , 7 ], therefore limiting access [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

Troup

Erridge

Ciesluk

et al. 2022

IJERPH

View full text Add to dashboard Cite

Cannabis-based medicinal products (CBMPs) are prescribed with increasing frequency. This study aimed to investigate the perceived stigma attached to patients prescribed CBMPs in the UK to establish its prevalence. A qualitative survey was developed by an expert multidisciplinary group and data were collected via Qualtrics. In total, 2319 patients on CBMP therapy were invited to take part in this study. 450 (19.4%) participants completed the questionnaire. In total, 81.3% (n = 366), 76.9% (n = 346), and 61.3% (n = 276) of participants reported feeling very comfortable or comfortable telling friends, family, and medical professionals, respectively, about their treatment. Participants thought that friends (n = 372; 82.7%) and family (n = 339; 75.3%) were very approving or somewhat approving of their CBMP prescription. However, participants thought that only 37.8% (n = 170) of healthcare professionals and 32.9% (n = 148) of society in general were very approving or somewhat approving of their CBMP prescription. 57.1% (n = 257), 55.3% (n = 249), and 40.2% (n = 181) of participants were afraid of what the police or criminal justice system, other government agencies, and healthcare professionals might think about their treatment. This study highlights those patients treated with CBMPs experience a high prevalence of perceived stigma from many corners of society. Future work should be undertaken to explore strategies to reduce perceived stigma at an individual and community level to avoid discrimination of patients, likely increasing appropriate access.

show abstract

Section: Introductionmentioning

confidence: 99%

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

Troup

Erridge

Ciesluk

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…This Scheduling of cannabis defines it as both possessing a high potential for abuse while having no approved medical uses [ 4 ]. This definition of cannabis under federal law not only greatly impedes research efforts to determine any true therapeutic benefits [ 5 , 6 ], psychoactive or otherwise, but it is possible that it creates feelings of immorality surrounding its use.…”

Section: Introductionmentioning

confidence: 99%

Differences in Attitudes Toward Medical Cannabis With Humanized Patient Scenarios

Clobes¹,

Arellano²,

Gagnon³

et al. 2022

Cureus

View full text Add to dashboard Cite

IntroductionAttitudes toward medical cannabis are shaped by a number of factors, such as religion, previous use, and political affiliation. Individuals with less supportive beliefs toward cannabis, in general, may be more open to its therapeutic applications in a humanized patient scenario (PS). MethodsA modified medical cannabis attitude scale was used to measure participants' attitudes toward medical cannabis. Two humanized patient scenarios were presented to the participants, and their level of agreement with the patient having access to medical cannabis was measured. After the scales were standardized, a Wilcoxon signed-rank test (WSR) was utilized to determine whether a difference between medical cannabis attitudes and approval of medical cannabis use in the humanized PS exists. ResultsA total of 645 participants completed the full survey and were included in the data analysis. Most participants were supportive of the patients in the humanized scenarios having access to medical cannabis; 76.1% and 75.7% of respondents, in each of the scenarios, selected the highest level of approval. There was a significantly higher approval for medical cannabis with the PS than attitudes toward medical cannabis in general (Z=-17.415, p<0.0005). ConclusionIndividuals were more supportive of patient access to medical cannabis when exposed to humanized PS than their general attitudes toward medical cannabis indicated. Applying the results of this current research, a viable plan to reduce the stigma surrounding cannabis is to use patient testimonials in public-facing advocacy efforts regarding medical cannabis.

show abstract

“…4 Chronic pain is one of the major reasons for MC use. [5][6][7][8] Within this context, several countries have introduced legislation in the past two decades to legalize cannabis for therapeutic use. Despite the evident shifts in legislation internationally, there has not been the same progress in building the evidence base of randomized clinical trials to support the use of MC for chronic pain.…”

Section: Introductionmentioning

confidence: 99%

“…Ineffective analgesia and a preference for nonopioid treatment are known precipitators for patients to explore the use of MC 4 . Chronic pain is one of the major reasons for MC use 5–8 …”

Section: Introductionmentioning

confidence: 99%

Healthcare professionals' perspectives on the use of medicinal cannabis to manage chronic pain: A systematic search and narrative review

et al. 2022

View full text Add to dashboard Cite

Rationale, aims, and objectives: Chronic pain is a global public health problem that negatively impacts individuals' quality of life and imposes a substantial economic burden on societies. The use of medicinal cannabis (MC) is often considered by patients to help manage chronic pain as an alternative or supplement to more conventional treatments, given enabling legalization in a number of countries.However, healthcare professionals involved in providing guidance for patients related to MC are often doing so in the absence of strong evidence and clinical guidelines. Therefore, it is crucial to understand their perspectives regarding the clinical use and relevance of MC for chronic pain. As little is known about attitudes of HCPs with regard to MC use for chronic pain specifically, the aim of this review was to identify and synthesize the published evidence on this topic. Methods: A systematic search was conducted across six databases: MEDLINE, EMBASE, CINAHL, Scopus, Web of Science, and PubMed from 2001 to March 26, 2021. Three authors independently performed the study selection and data extraction. Thematic analysis was undertaken to identify key themes. Results: A total of 26 studies were included, involving the United States, Israel, Canada, Australia, Ireland, and Norway, and the perspectives of physicians, nurses, and pharmacists. Seven key themes were identified: MC as a treatment option for chronic pain, and perceived indicated uses; willingness to prescribe MC; legal issues; low perceived knowledge and the need for education; comparative safety of MC versus opioids; addiction and abuse; and perceived adverse effects; Conclusion:To support best practice in the use of MC for chronic pain, healthcare professionals require education and training, as well as clinical guidelines that provide evidence-based information about efficacy, safety, and appropriate dosage of products for this indication. Until these gaps are addressed, healthcare professionals will be limited in their capacity to make treatment recommendations about MC for people/patients with chronic pain.

show abstract

Mixed methods study of the potential therapeutic benefits from medical cannabis for patients in Florida

Cited by 22 publications

References 18 publications

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

Differences in Attitudes Toward Medical Cannabis With Humanized Patient Scenarios

Healthcare professionals' perspectives on the use of medicinal cannabis to manage chronic pain: A systematic search and narrative review

Contact Info

Product

Resources

About